Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors, today announced the initiation of a Phase 1, double-blind, randomized, placebo-controlled, single and multiple-dose study to evaluate the safety, pharmacokinetics, and pharmacodynamics of CRN01941 in healthy volunteers.
What is CRN01941?
It’s an oral nonpeptide somatostatin receptor subtype 2 (sst2) biased agonist* designed for the treatment of neuroendocrine tumors (NETs) that originate from neuroendocrine cells commonly found in the gut, lung, or pancreas. From the detail contained in the clinical trials document (see below), it appears to involve a capsule. I’m guessing that the use of terms such as ‘non-peptide’ means that it may not be the same as a somatostatin analogue, but the method of operation appear to be similar in that it wants to bind to somatostatin receptor 2 (SST2). I will bring more technical detail once I have it. * chemical that binds to a receptor and activates the receptor to produce a biological response.
This trial launch follows other products including a similar capsule based somatostatin receptor product for treating Acromegaly called CRN00808, currently undergoing two Phase 2 clinical trials. The company is also developing oral nonpeptide somatostatin agonists for hyperinsulinism, as well as oral nonpeptide ACTH antagonists for the treatment of Cushing’s disease.
On the basis that the CRN00808 Phase 2 trial for Acromegaly is using patients previously treated with somatostatin analog based treatment regimens, I suspect this drug is designed for the same market as Sandostatin LAR/Octreotide and Somatuline (Lanreotide). For more information, please visit http://www.crinetics.com.
The Phase 1 Clinical Trial of CRN01941 for NETs
The trial is initially only based in Perth Western Australia, it is not yet known if there are any plans to expand locations in subsequent phases or parts of the trial. It also appears they are trialling the use of a capsule based drug and another delivery method as yet unknown, the clinical trial only mentions “Oral Solution” so it isn’t an injection. Read more at ClinicalTrials.gov using the identifier NCT03936166.
This is not the first somatostatin receptor based product in the pipeline, please also check out my article about Somatostatin Analogues and Delivery Mechanisms in the pipeline – click here.
Summary of sources:
Thanks for reading